European Society for Medical Oncology, 2024 - Older patients
Deployment of RPM in Oncology Among Elderly Patients: A Real-World Study of 4,538 Patients Across 84 Centers in France and Belgium.
Dec 4, 2025
2 minutes
Authors
Nicolas Bertrand 1, Thomas Grellety 2, Maximilien Autherman 3, Romain Rivoirard 4, Rabia Boulahssass 5, Etienne Brain 6, Loïc Mourey 7, Claire Dumas-Bonnetain 8, Philippe Caillet 9, Maxime Frelaut 10, Berengère Beauplet 11, Michael Bringuier 6, Camille Chakiba 12, Anne-Laure Couderc 13, Florence Canouï-Poitrine 14, Capucine Baldini 10.
Affiliation
1. Centre Eugène Marquis, Rennes, France ; 2. Centre Hospitalier de la Côte Basque, Bayonne, France ; 3. Resilience, Paris, France ; 4. Hôpital Privé de la Loire, Saint-Etienne, France ; 5. Centre Hospitalier Universitaire de Nice, Nice, France ; 6. Institut Curie, Paris, France ; 7. Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France ; 8. Unicancer, Paris, France ; 9. Hôpital Européen Georges Pompidou, Paris, France ; 10. Gustave Roussy, Villejuif, France ; 11. Centre Hospitalier Universitaire de Caen, Caen, France ; 12. Institut Bergonié, Bordeaux, France ; 13. Assistance Publique des Hôpitaux de Marseille, Marseille, France ; 14. Assistance Publique des Hôpitaux de Paris, Hôpital Henri Mondor, Créteil, France.
Introduction
Medical remote monitoring based on ePROs (electronic Patient-Reported Outcomes) has demonstrated clinical and organizational benefits through Phase III randomized controlled clinical trials [1-4]. These benefits include:
- Symptom control,
- Quality of life,
- Increased relative dose intensity,
- Reduction in the number of hospitalizations,
- Prolongation of overall survival.
Consequently, in 2022, ESMO published its recommendations regarding medical remote monitoring for routine clinical practice during anti-cancer treatments[5].
However, patient adherence and the benefits of remote monitoring in elderly patients remain unknown. This study presents and evaluates the deployment of medical remote monitoring in routine care for older adults undergoing anti-cancer treatment in France and Belgium.
Poster presented at the 2024 ESMO (European Society of Medical Oncology) Congress.
Sources
1. Mir O, Ferrua M, Fourcade A, et al. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med.2022;28(6):1224-1231.
2. Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA. 2022;327(24):2413-2422.
3. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2019 Feb20;37(6):528.
4. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA.2017;318(2):197-198.
5. Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33(9):878-892. doi:10.1016/j.annonc.2022.04.007
